Atrial fibrillation management: evaluating rate vs rhythm control

References

• Ball J, Carrington MJ, McMurray JJ, et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167:1807–1824.
   PubMed Web of Science ®Google Scholar
• Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2013;129:837–847.
   PubMed Web of Science ®Google Scholar
• Patel NJ, Deshmukh A, Pant S, et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation. 2014;129:2371–2379.
   PubMed Web of Science ®Google Scholar
• Mamas MA, Caldwell JC, Chacko S, et al. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail. 2009;11:676–683.
   PubMed Web of Science ®Google Scholar
• Nikolaidou T, Channer K. Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J. 2009;85:303–312.
   PubMed Web of Science ®Google Scholar
• Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33:304–310.
   PubMed Web of Science ®Google Scholar
• Maragno I, Santostasi G, Gaion RM, et al. Low- and medium-dose diltiazem in chronic atrial fibrillation: comparison with digoxin and correlation with drug plasma levels. Am Heart J. 1988;116:385–392.
   PubMed Web of Science ®Google Scholar
• Botto GL, Bonini W, Broffoni T. Modulation of ventricular rate in permanent atrial fibrillation: randomized, crossover study of the effects of slow-release formulations of gallopamil, diltiazem, or verapamil. Clin Cardiol. 1998;21:837–840.
   PubMed Web of Science ®Google Scholar
• Lewis RV, Laing E, Moreland TA, et al. A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. Eur Heart J. 1988;9:279–283.
   PubMed Web of Science ®Google Scholar
• Roth A, Harrison E, Mitani G, et al. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation. 1986;73:316–324.
   PubMed Web of Science ®Google Scholar
• Olshansky B, Rosenfeld LE, Warner AL, et al. The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. J Am Coll Cardiol. 2004;43:1201–1208.
   PubMed Web of Science ®Google Scholar
• Ahmad K, Dorian P. Rate control in atrial fibrillation: looking beyond the average heart rate. Curr Opin Cardiol. 2006;21:88–93.
   PubMed Web of Science ®Google Scholar
• Chao T-F, Liu C-J, Tuan T-C, et al. Rate-control treatment and mortality in atrial fibrillation. Circulation. 2015;132:1604–1612.
   PubMed Web of Science ®Google Scholar
• Hallberg P, Lindbäck J, Lindahl B, et al. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol. 2007;63:959–971.
   PubMed Web of Science ®Google Scholar
• Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation. J Am Coll Cardiol. 2014;64:660–668.
   PubMed Web of Science ®Google Scholar
• Freeman JV, Reynolds K, Fang M, et al. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol. 2015;8:49–58.
   PubMed Web of Science ®Google Scholar
• Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010;21:1550–1559.
   PubMed Web of Science ®Google Scholar
• Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin–analysis from the AFFIRM study. Eur Heart J. 2013;34:1481–1488.
   PubMed Web of Science ®Google Scholar
• Friberg L, Hammar N, Rosenqvist M. Digoxin in atrial fibrillation: report from the Stockholm Cohort study of atrial fibrillation (SCAF). Heart. 2010;96:275–280.
   PubMed Web of Science ®Google Scholar
• Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533.
   PubMed Web of Science ®Google Scholar
• David D, Segni ED, Klein HO, et al. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol. 1979;44:1378–1382.
   PubMed Web of Science ®Google Scholar
• Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003;42(11):1944–1951.
   PubMed Web of Science ®Google Scholar
• DiBianco R, Morganroth J, Freitag JA, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J. 1984;108:1121–1127.
   PubMed Web of Science ®Google Scholar
• Channer KS, Papouchado M, James MA, et al. Towards improved control of atrial fibrillation. Eur Heart J. 1987;8:141–147.
   PubMed Web of Science ®Google Scholar
• Panidis IP, Morganroth J, Baessler C. Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. Am J Cardiol. 1983;52:1197–1201.
   PubMed Web of Science ®Google Scholar
• Klein HO, Pauzner H, Di Segni E, et al. The beneficial effects of verapamil in chronic atrial fibrillation. Arch Intern Med. 1979;139:747–749.
   PubMedGoogle Scholar
• Koh KK, Song JH, Kwon KS, et al. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study. Int J Cardiol. 1995;52:167–174.
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833.
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363–1373.
   PubMed Web of Science ®Google Scholar
• Tse HF, Lam YM, Lau CP, et al. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol. 2001;28:446–450.
   PubMed Web of Science ®Google Scholar
• Kochiadakis GE, Kanoupakis EM, Igoumenidis NE, et al. Efficacy and safety of oral amiodarone in controlling heart rate in patients with persistent atrial fibrillation who have undergone digitalisation. Hellenic J Cardiol. 2005;46:336–340.
   PubMedGoogle Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2014;2014(21):e1–e76.
   Google Scholar
• Steinberg BA, Kim S, Thomas L, et al. Increased heart rate is associated with higher mortality in patients with atrial fibrillation (AF): results from the outcomes registry for better informed treatment of AF (ORBIT‐AF). J Am Heart Assoc. 2015;4:e002031.
   Google Scholar
• Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the canadian cardiovascular society guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30(10):1114–1130.
   PubMed Web of Science ®Google Scholar
• The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989;321:406–412.
   PubMed Web of Science ®Google Scholar
• Reimold SC, Maisel WH, Em A. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis. Am J Cardiol. 1998;82:66N–71N.
   Google Scholar
• Kyles AE, Murdock CJ, Yeung-Lai-Wah JA, et al. Long term efficacy of propafenone for prevention of atrial fibrillation. Can J Cardiol. 1991;7:407–409.
   PubMed Web of Science ®Google Scholar
• Tarquinii M, Lolli C, Foscoli M, et al. Prevention of paroxysmal atrial fibrillation with propafenone after withdrawal of amiodarone because of side effects. Clin Ter. 1993;142:341–346.
   PubMedGoogle Scholar
• Hohnloser SH, Zabel M. Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol. 1992;70:3A–9A; discussion 9A–10A.
   PubMed Web of Science ®Google Scholar
• Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol. 1996;77:66A–71A.
   PubMed Web of Science ®Google Scholar
• Saklani P, Skanes A. Novel anti-arrhythmic medications in the treatment of atrial fibrillation. Curr Cardiol Rev. 2012;8:302–309.
   PubMedGoogle Scholar
• Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1998;81:995–998.
   PubMed Web of Science ®Google Scholar
• Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000;102:2385–2390.
   PubMed Web of Science ®Google Scholar
• Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation. 2001;104:292–296.
   PubMed Web of Science ®Google Scholar
• McClellan KJ, Markham AM. Dofetilide: a review of its use in atrial fibrillation and atrial flutter. Drugs. 1999;58:1043–1059.
   PubMed Web of Science ®Google Scholar
• Le Heuzey J-Y, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597–605.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268–2276.
   PubMed Web of Science ®Google Scholar
• Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–2687.
   PubMed Web of Science ®Google Scholar
• Prystowsky EN, Padanilam BJ, Fogel RI. Treatment of atrial fibrillation. JAMA. 2015;314:278.
   PubMed Web of Science ®Google Scholar
• Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med. 2004;351:2384–2391.
   PubMed Web of Science ®Google Scholar
• Khan I. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003;87:121–128.
   PubMed Web of Science ®Google Scholar
• Khan I. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol. 2001;37:542–547.
   PubMed Web of Science ®Google Scholar
• Khan IA, Mehta NJ, Gowda R. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003;89:239–248.
   PubMed Web of Science ®Google Scholar
• Murray KT. Ibutilide. Circulation. 1998;97(5):493–497.
   PubMed Web of Science ®Google Scholar
• Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 1996;94:1613–1621.
   PubMed Web of Science ®Google Scholar
• Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 1998;31:1414–1419.
   PubMed Web of Science ®Google Scholar
• Stiell IG, Clement CM, Perry JJ, et al. Association of the Ottawa aggressive protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter. CJEM. 2010;12:181–191.
   PubMedGoogle Scholar
• Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–1840.
   PubMed Web of Science ®Google Scholar
• Chen HS, Wen JM, Wu SN, et al. Catheter ablation for paroxysmal and persistent atrial fibrillation. Cochrane Database Syst Rev. 2012 Apr 18;4:CD007101.
   Web of Science ®Google Scholar
• Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012;367:1587–1595.
   PubMed Web of Science ®Google Scholar
• Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2). JAMA. 2014;311:692.
   PubMed Web of Science ®Google Scholar
• Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. J Am Coll Cardiol. 2006;48:2340–2347.
   PubMed Web of Science ®Google Scholar
• Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010;303:333–340.
   PubMed Web of Science ®Google Scholar
• Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J. 2006;27:216–221.
   PubMed Web of Science ®Google Scholar
• Terasawa T, Balk EM, Chung M, et al. Systematic review: comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation. Ann Intern Med. 2009;151:191–202.
   PubMed Web of Science ®Google Scholar
• Ganesan AN, Shipp NJ, Brooks AG, et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2:e004549.
   PubMed Web of Science ®Google Scholar
• Lee G, Sanders P, Kalman JM. Catheter ablation of atrial arrhythmias: state of the art. Lancet. 2012;380:1509–1519.
   PubMed Web of Science ®Google Scholar
• Brooks AG, Stiles MK, Laborderie J, et al. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review. Heart Rhythm. 2010;7:835–846.
   PubMed Web of Science ®Google Scholar
• Wynn GJ, Das M, Bonnett LJ, et al. Efficacy of catheter ablation for persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials. Circ Arrhythm Electrophysiol. 2014;7:841–852.
   PubMed Web of Science ®Google Scholar
• Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372:1812–1822.
   PubMed Web of Science ®Google Scholar
• Narayan S, Krummen D, Shivkumar K, et al. Treatment of atrial fibrillation by the ablation of localized sources. J Am Coll Cardiol. 2012;60:628–636.
   PubMed Web of Science ®Google Scholar
• Narayan S, Baykaner T, Clopton P, et al. Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared with trigger ablation alone. J Am Coll Cardiol. 2014;63:1761–1768.
   PubMed Web of Science ®Google Scholar
• Bai R, Di Biase L, Mohanty P, et al. Proven isolation of the pulmonary vein antrum with or without left atrial posterior wall isolation in patients with persistent atrial fibrillation. Heart Rhythm. 2016;13:132–140.
   PubMed Web of Science ®Google Scholar
• Packer DL, Kowal RC, Wheelan KR, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation. J Am Coll Cardiol. 2013;61:1713–1723.
   PubMed Web of Science ®Google Scholar
• Andrade JG, Khairy P, Guerra PG, et al. Efficacy and safety of cryoballoon ablation for atrial fibrillation: a systematic review of published studies. Heart Rhythm. 2011;8:1444–1451.
   PubMed Web of Science ®Google Scholar
• Di Giovanni G, Wauters K, Chierchia G-B, et al. One-year follow-up after single procedure Cryoballoon ablation: a comparison between the first and second generation balloon. J Cardiovasc Electrophysiol. 2014;25:834–839.
   PubMed Web of Science ®Google Scholar
• Fürnkranz A, Bordignon S, Dugo D, et al. Improved 1-year clinical success rate of pulmonary vein isolation with the second-generation cryoballoon in patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2014;25:840–844.
   PubMed Web of Science ®Google Scholar
• Koektuerk B, Yorgun H, Hengeoez O, et al. Cryoballoon ablation for pulmonary vein isolation in patients with persistent atrial fibrillation. Circ Arrhythm Electrophysiol. 2015;8:1073–1079.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Dorwarth U, Andresen D, et al. Cryoballoon versus RF ablation in paroxysmal atrial fibrillation: results from the German Ablation Registry. J Cardiovasc Electrophysiol. 2014;25:1–7.
   PubMed Web of Science ®Google Scholar
• Straube F, Dorwarth U, Ammar-Busch S, et al. First-line catheter ablation of paroxysmal atrial fibrillation: outcome of radiofrequency vs. cryoballoon pulmonary vein isolation. Europace. 2015;pii:euv271. Epub ahead of print
   Google Scholar
• Luik A, Radzewitz A, Kieser M, et al. Cryoballoon versus open irrigated radiofrequency ablation in patients with paroxysmal atrial fibrillation: the prospective, randomized, controlled, noninferiority freezeAF study. Circulation. 2015;132:1311–1319.
   PubMed Web of Science ®Google Scholar
• Fürnkranz A, Brugada J, Albenque JP, et al. Rationale and design of FIRE AND ICE: a multicenter randomized trial comparing efficacy and safety of pulmonary vein isolation using a cryoballoon versus radiofrequency ablation with 3D-reconstruction. J Cardiovasc Electrophysiol. 2014;25:1314–1320.
   PubMed Web of Science ®Google Scholar
• Scheinman MM, The HS. NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol. 1998;2000(23):1020–1028.
   Google Scholar
• Curtis AB, Kutalek SP, Prior M, et al. Prevalence and characteristics of escape rhythms after radiofrequency ablation of the atrioventricular junction: results from the registry for AV junction ablation and pacing in atrial fibrillation. Ablate and Pace Trial Investigators. Am Heart J. 2000;139:122–125.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AP, Kourouyan HD, Siu A, et al. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J. 1996;131:499–507.
   PubMed Web of Science ®Google Scholar
• Weerasooriya R, Davis M, Powell A, et al. The Australian intervention randomized control of rate in atrial fibrillation trial (AIRCRAFT). J Am Coll Cardiol. 2003;41:1697–1702.
   PubMed Web of Science ®Google Scholar
• Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med. 2001;344:1043–1051.
   PubMed Web of Science ®Google Scholar
• Brown CS, Mills RM Jr, Conti JB, et al. Clinical improvement after atrioventricular nodal ablation for atrial fibrillation does not correlate with improved ejection fraction. Am J Cardiol. 1997;80:1090–1091.
   PubMed Web of Science ®Google Scholar
• Marshall HJ, Harris ZI, Griffith MJ, et al. Prospective randomized study of ablation and pacing versus medical therapy for paroxysmal atrial fibrillation: effects of pacing mode and mode-switch algorithm. Circulation. 1999;99:1587–1592.
   PubMed Web of Science ®Google Scholar
• Yin J, Hu H, Wang Y, et al. Effects of atrioventricular nodal ablation on permanent atrial fibrillation patients with cardiac resynchronization therapy: a systematic review and meta-analysis. Clin Cardiol. 2014;37:707–715.
   PubMed Web of Science ®Google Scholar
• Bajaj NS, Bhatia V, Sanam K, et al. Impact of atrial fibrillation and heart failure, independent of each other and in combination, on mortality in community-dwelling older adults. Am J Cardiol. 2014;114:909–913.
   PubMed Web of Science ®Google Scholar
• Shah M, Avgil Tsadok M, Jackevicius CA, et al. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients >/=65 years of age with versus without heart failure. Am J Cardiol. 2014;114:401–406.
   PubMed Web of Science ®Google Scholar
• Mulder BA, Van Veldhuisen DJ, Crijns HJ, et al. Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study. Eur J Heart Fail. 2013;15:1311–1318.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Mañero M, Otero-Raviña F, García-Seara J, et al. Outcomes of a contemporary sample of patients with atrial fibrillation taking digoxin: results from the AFBAR study. Rev Esp Cardiol. 2014;67:890–897.
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998;98:2574–2579.
   PubMed Web of Science ®Google Scholar
• Cadrin-Tourigny J, Wyse DG, Roy D, et al. Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials. J Cardiovasc Electrophysiol. 2014;25(12):1306–1313.
   PubMed Web of Science ®Google Scholar
• Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–2677.
   PubMed Web of Science ®Google Scholar
• Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014;7:31–38.
   PubMed Web of Science ®Google Scholar
• Nedios S, Sommer P, Dagres N, et al. Long-term follow-up after atrial fibrillation ablation in patients with impaired left ventricular systolic function: the importance of rhythm and rate control. Heart Rhythm. 2014;11:344–351.
   PubMed Web of Science ®Google Scholar
• Anselmino M, Matta M, D’Ascenzo F, et al. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014;7:1011–1018.
   PubMed Web of Science ®Google Scholar
• van Boven N, Theuns D, Bogaard K, et al. Atrial fibrillation in cardiac resynchronization therapy with a defibrillator: a risk factor for mortality, appropriate and inappropriate shocks. J Cardiovasc Electrophysiol. 2013;24:1116–1122.
   PubMed Web of Science ®Google Scholar